Safety and immunogenicity after 2 doses of the BNT162b2 COVID-19 vaccine in an early-phase oncology trial centre population - Aix-Marseille Université Access content directly
Journal Articles European Journal of Cancer Year : 2021

Dates and versions

hal-03623103 , version 1 (29-03-2022)

Identifiers

Cite

Nausicaa Malissen, Laetitia Ninove, Xavier de Lamballerie, Nicolas André, Caroline Gaudy-Marqueste. Safety and immunogenicity after 2 doses of the BNT162b2 COVID-19 vaccine in an early-phase oncology trial centre population. European Journal of Cancer, 2021, 156, pp.125-126. ⟨10.1016/j.ejca.2021.07.040⟩. ⟨hal-03623103⟩
30 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More